Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 1/20 | 0.42 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631720 | 0.92 | ITPR3 (0.47) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL23631717 | 0.89 | ITPR3 (0.49) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL14727907 | 0.84 | LPAR3 (0.53) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL8768479 | 0.83 | PLA2G2C (0.38) | ITPR3ITPR1FDPSPLA2G2CLMNA | |
| SCHEMBL23631726 | 0.83 | ITPR3 (0.55) | ITPR3ITPR1LPAR3LPAR2LPAR1 | |
| SCHEMBL10885700 | 0.82 | LPAR3 (0.62) | LPAR3LPAR2LPAR1PLA2G2CTSHR | |
| Octadecylamine SCHEMBL9496217 | 0.82 | LPAR3 (0.62) | LPAR3LPAR2LPAR1PLA2G2CTSHR | |
| SCHEMBL22221628 | 0.82 | LPAR3 (0.62) | LPAR3LPAR2LPAR1PLA2G2CTSHR | |
| Dodecylamine SCHEMBL10887166 | 0.82 | LPAR3 (0.62) | LPAR3LPAR2LPAR1PLA2G2CTSHR | |
| SCHEMBL9496121 | 0.82 | LPAR3 (0.62) | LPAR3LPAR2LPAR1PLA2G2CTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9506060-B2 | LNA antisense oligonucleotides for the modulation of Myc expression | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160024495-A1 | LNA ANTISENSE OLIGONUCLEOTIDES FOR THE MODULATION OF MYC EXPRESSION | ENZON PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8450290-B2 | Methods for treating androgen receptor dependent disorders including cancers | ENZON PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450291-B2 | RNA antagonist compounds for the modulation of PIK3CA expression | SANTARIS PHARMA A/S (DK) | 2013-05-28 | — | — | US | disclosed |
| US-20120295955-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 | SANTARIS PHARMA A/S (DK) | 2012-11-22 | — | — | US | disclosed |
| US-8268793-B2 | RNA antagonist compounds for the modulation of HER3 | SANTARIS PHARMA A/S (DK) | 2012-09-18 | — | — | US | disclosed |
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | SANTARIS PHARMA A/S (DK) | 2012-03-29 | — | — | US | disclosed |
| US-20110319471-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | SANTARIS PHARMA A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| US-7989429-B2 | LNA antagonists targeting the androgen receptor | ENZON PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110152348-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | ENZON PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110077285-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | ENZON PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7863437-B2 | RNA antagonist compounds for the modulation of PIK3CA expression | ENZON PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100323967-A1 | RNA Antagonist Compounds for the Modulation of MCL-1 | SANTARIS PHARMA A/S (DK) | 2010-12-23 | — | — | US | disclosed |
| US-20100234451-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7737125-B2 | LNA antagonists targeting the androgen receptor | ENZON PHARAMACEUTICALS, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090192110-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | SANTARIS PHARMA A/S | 2009-07-30 | — | — | US | disclosed |
| US-20090005335-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295955-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 | ERBB3, EGFR, ERBB2 | ITPR3 2335/4885ITPR1 3442/4885LPAR3 73/4885 |
| US-20110152348-A1 | METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS | AR, ESRRB, ESRRA | ITPR3 2828/4885ITPR1 2743/4885LPAR3 144/4885 |
| US-20090005335-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | CTNNB1, CTNNA1, WNT1 | ITPR3 3597/4885ITPR1 3674/4885LPAR3 350/4885 |
| US-20090192110-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | PIK3CA, PIK3R4, PIK3R5 | ITPR3 1557/4885ITPR1 1449/4885LPAR3 543/4885 |
| US-20100234451-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | AR, ESRRB, LHCGR | ITPR3 3808/4885ITPR1 3944/4885LPAR3 16/4885 |
| US-20110077285-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION | PIK3CA, PIK3R4, PIK3R5 | ITPR3 1789/4885ITPR1 1710/4885LPAR3 538/4885 |
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ERBB3, ERBB2, EGFR | ITPR3 741/4885ITPR1 2069/4885LPAR3 39/4885 |
| US-20110319471-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | AR, ESRRB, LHCGR | ITPR3 3808/4885ITPR1 3944/4885LPAR3 16/4885 |
| US-20100323967-A1 | RNA Antagonist Compounds for the Modulation of MCL-1 | MCL1, NSUN2, MCTS1 | ITPR3 2368/4885ITPR1 1795/4885LPAR3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.